Alcohol Treatment Boosts Hep C Cure Rates Among Drinkers People who drink—even heavily—can successfully undergo treatment for hepatitis C virus (HCV) if they’re provided with individualized, multidisciplinary care that also addresses their alcohol use, according to a study published in the February 2012 issue of Journal of Hepatology.
January 26, 2012
New Gilead GS 7340-Inclusive Fixed-Dose Combo Tablet Trial Announced Gilead Sciences Inc. (Nasdaq: GILD) today announced the start of a Phase II clinical trial to evaluate a modified version of its experimental “quad” fixed-dose combination (FDC) tablet currently being reviewed by the U.S. Food and Drug Administration, according to a company announcement.
January 25, 2012
Less than 1 in 2 HIV-Positive U.S. Residents Are in Regular Care Less than half of people living with HIV in the United States are being retained in ongoing medical care, according to a new analysis by U.S. Centers for Disease Control and Prevention (CDC) investigators published online ahead of print by the Journal of Acquired Immune Deficiency Syndromes. The sobering statistics, which include the finding that only two thirds of people testing positive for HIV are being successfully linked to medical care within a year of their diagnosis, help explain those of another recent CDC analysis indicating that only 28 percent of U.S. residents living with HIV have undetectable viral loads.
January 24, 2012
Many at Risk for Hep B in U.S. Aren't Getting Vaccinated
Missed opportunities to vaccinate people at the highest risk for hepatitis B virus (HBV) explain why 80,000 people continue to be infected ever year in the United States, according to a new study published online ahead of print by the journal Infection.
January 20, 2012
Viread Approved for Children 2 and Up Viread (tenofovir), Gilead Sciences’ nucleotide reverse transcriptase inhibitor, has been approved for children living with HIV, according to a U.S. Food and Drug Administration (FDA) announcement. To facilitate correct pediatric use of the drug, the agency also approved a powder formulation for children between the ages of 2 and 5 and low-dose tablets to meet pediatric dosing needs.
January 19, 2012
Vitamin D May Protect Bone Health in Tenofovir Takers Vitamin D supplementation may help prevent hormonal changes that can lead to bone loss among adolescents and young adults being treated for HIV with tenofovir—found in Viread, Truvada and Atripla—according to a National Institutes of Health (NIH) study published online ahead of print by Clinical Infectious Diseases.
An Aspirin a Day to Keep HIV-Related Cervical Cancer Away? Might an aspirin a day help keep cervical cancer away? Though there aren’t yet any studies indicating it will, researchers have uncovered a biological connection between HIV-associated inflammation and cervical cancer that may be curtailed by the affordable and widely available drug.
Many Young HIV-Positive Women May Benefit From Cervical Cancer Vaccine Young women living with HIV may benefit from vaccinations that protect against cervical cancer, according to a new study showing that many HIV-positive women averaging 21 years of age are negative for the human papillomavirus (HPV) types typically associated with tumors, according to a new analysis. These encouraging findings were presented at the 2nd International Workshop on HIV and Women, held January 9 and 10 in Bethesda, Maryland, and were reported by the National AIDS Treatment Activist Project (NATAP).
January 13, 2012
Study Confirms Viral Load Most Important Predictor of HIV Transmission A new African study of heterosexual HIV-serodiscordant couples—in which one partner is positive and the other is negative—confirms that viral load is the most important factor influencing the risk of transmitting the virus, according to data published in the February 1 issue of The Journal of Infectious Diseases. The findings also stress the importance of other transmission variables, including condom use, age, male circumcision status and the presence of other sexually transmitted infections (STIs).
January 12, 2012
Occasional Marijuana Smoking Does Not Impair Lung Function
Potential good news for marijuana users—occasionally smoking pot did not affect pulmonary function and may actually increase lung airflow rates and lung capacity, according to a new study published in the January 11 issue of The Journal of the American Medical Association (JAMA). Though the study does not speak to the pulmonary effects of marijuana smoking by people living with HIV, the results will likely help guide risk-versus-benefit analyses of marijuana use to alleviate a variety of disease-related symptoms.
January 11, 2012
Depression More Common Among HIV-Positive Women Than Men Depression is more common among women living with HIV, compared with men living with HIV, according to an international study reported at the 2nd International Workshop on HIV and Women, held January 9 and 10 in Bethesda, Maryland, and highlighted by the National AIDS Treatment Advocacy Project (NATAP).
New Guidelines: Anti-Seizure Drug Selection for People Living With HIV New guidelines from the American Academy of Neurology (AAN) and the International League Against Epilepsy (ILAE) have been published online ahead of print by the journal Neurology to help people living with HIV and their care providers choose seizure drugs that do not interact negatively with antiretrovirals (ARVs).
January 05, 2012
Effective Vaccine Against Virulent SIV Raises Hope for HIV
Researchers are reporting a high degree of success using a two-step vaccine strategy against a virulent, tough-to-neutralize form of simian immunodeficiency virus (SIV) in monkeys, findings that could potentially spell success against HIV in humans, according to a paper published online by the journal Nature.
January 03, 2012
Experts Issue Early Guide for Hep C Protease Inhibitor Therapy in People Living with HIV A small but influential group of hepatitis C virus (HCV) experts has published provisional guidelines on the use of HCV protease inhibitors (PIs) in people living with HIV. The guidelines, published ahead of print by Clinical Infectious Diseases, are based in part on recommendations made to the Maryland AIDS Drug Assistance Program (ADAP) to help guide the use of these drugs in people coinfected with both viruses in the absence of official approvals from the U.S. Food and Drug Administration (FDA) and complete clinical trial results.
More Treatment News
Have news about HIV? Send press releases, news tips and other announcements to email@example.com.